Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT1419 in R/R Myeloid or B-cell Malignancies
NCT05107856Phase 1Terminated
- Sponsor
- Prelude Therapeutics
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PRT1419 in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS) and 8 more (3 arms), sponsored by Prelude Therapeutics. Primary endpoints: Dose limiting toxicities at Day 28, Safety and tolerability of PRT1419 at 3 years and 1 more. Started Mar 2022; status: terminated.
02
Drugs
PRT1419
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)Myelodysplastic/myeloproliferative neoplasm overlap syndrome (MDS/MPN)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05107856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107856.